2.71
-0.14(-4.91%)
Currency In USD
| Previous Close | 2.85 |
| Open | 2.85 |
| Day High | 2.85 |
| Day Low | 2.7 |
| 52-Week High | 13.91 |
| 52-Week Low | 1.11 |
| Volume | 319,051 |
| Average Volume | 511,283 |
| Market Cap | 52.81M |
| PE | -1.21 |
| EPS | -2.24 |
| Moving Average 50 Days | 2.27 |
| Moving Average 200 Days | 4.22 |
| Change | -0.14 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $294.99 as of July 11, 2025 at a share price of $2.829. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 3 years ago, it would be worth $199.79 as of July 11, 2025 at a share price of $2.829.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis to Attend the AAIC 2025 with Four Poster Presentations
GlobeNewswire Inc.
Jun 26, 2025 12:00 PM GMT
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
GlobeNewswire Inc.
Jun 19, 2025 10:30 AM GMT
MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease
Annovis to Host Webinar and Live Q&A on June 24, 2025
GlobeNewswire Inc.
Jun 05, 2025 12:00 PM GMT
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parki